Sebela International

Sebela Pharmaceuticals is a specialty pharmaceutical company dedicated to delivering innovative therapies in gastroenterology, women's health, and dermatology. The company possesses a strong commercial infrastructure in the United States, supported by a portfolio of market-leading products such as Sutab and SuPrep for colonoscopy preparation. Sebela's growth strategy involves both internal development and the acquisition of late-stage or commercial assets, exemplified by its 2018 acquisition of Braintree Laboratories. Its late-stage pipeline includes tegoprazan, a potassium-competitive acid blocker (P-CAB) for gastrointestinal disorders, and VeraCept, a novel long-acting reversible contraceptive. Headquartered in Roswell, Georgia, and Dublin, Ireland, the company is backed by Water Street Healthcare Partners. Sebela continues to expand its footprint through strategic partnerships and a focus on high-unmet-need therapeutic areas.